Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | BMP1 | P13497 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 4/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | BCL9 | O00512 | 1/20 | 0.30 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037107 | 0.97 | REN (0.36) | RENRIPK1GRM5BMP1RORC | |
| SCHEMBL3268900 | 0.96 | REN (0.32) | RENBMP1RORCCTSK | |
| SCHEMBL2338242 | 0.96 | BMP1 (0.35) | RENGRM5BMP1BCL9CTNNB1 | |
| SCHEMBL3269224 | 0.95 | UTS2R (0.34) | RENRIPK1BCL9CTNNB1 | |
| SCHEMBL3267629 | 0.95 | REN (0.32) | RENBMP1RORC | |
| SCHEMBL1037839 | 0.95 | REN (0.36) | RENGRM5BMP1RORC | |
| SCHEMBL4582802 | 0.94 | REN (0.35) | RENGRM5BMP1TMEM97SIGMAR1 | |
| SCHEMBL3272138 | 0.94 | REN (0.35) | RENGRM5BMP1TMEM97SIGMAR1 | |
| SCHEMBL3274090 | 0.94 | BMP1 (0.31) | RENRIPK1BMP1RORC | |
| SCHEMBL2340320 | 0.94 | REN (0.35) | RENGRM5TMEM97SIGMAR1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799779-B2 | Substituted piperidines as renin inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-1863802-B1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2010-06-16 | — | — | EP | disclosed |
| US-20090306064-A1 | Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| EP-1987834-A2 | Substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306064-A1 | Substituted Piperidines as Renin Inhibitors | REN, AGTR1, ACE | REN 1/4885RIPK1 4628/4885GRM5 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.